Treatment of inflammatory myopathies

被引:0
作者
Mastaglia, FL
Phillips, BA
Zilko, P
机构
[1] QUEEN ELIZABETH II MED CTR,DEPT MED,PERTH,WA 6009,AUSTRALIA
[2] QUEEN ELIZABETH II MED CTR,DEPT NEUROL,PERTH,WA 6009,AUSTRALIA
[3] QUEEN ELIZABETH II MED CTR,DEPT CLIN IMMUNOL,PERTH,WA 6009,AUSTRALIA
关键词
inflammatory myopathies; treatment; polymyositis; dermatomyositis; inclusion body myositis;
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The treatment of the immune-mediated inflammatory myopathies remains largely empirical. Corticosteroids are usually effective in polymyositis and dermatomyositis but may need to be combined with methotrexate or azathioprine in some patients, Intravenous immunoglobulin (IVIg) is effective as add-on therapy in some patients not adequately controlled with steroids or immunosuppressive agents, but further controlled trials of IVIg are necessary to define the indications and optimal dose regimens. Cyclophosphamide, cyclosporin, or chlorambucil may be effective in patients with refractory polymyositis or dermatomyositis. Low-dose whole body or lymphoid irradiation is a last option in severely disabled patients resistant to all other treatments. As a small proportion of patients with inclusion body myositis respond to corticosteroid or immunosuppressive therapy, a 3-6-month trial of such therapy is justified in this condition. More specific immunotherapy for these disorders awaits identification of the target antigens and further clarification of the immunopathogenetic mechanisms. (C) 1997 John Wiley & Sons, Inc.
引用
收藏
页码:651 / 664
页数:14
相关论文
共 50 条
  • [1] Treatment of idiopathic inflammatory myopathies
    Amato, AA
    Griggs, RC
    CURRENT OPINION IN NEUROLOGY, 2003, 16 (05) : 569 - 575
  • [2] Evaluation and treatment of the idiopathic inflammatory myopathies
    Amato, AA
    Barohn, RJ
    NEUROLOGIST, 2000, 6 (05) : 267 - 287
  • [3] Current pharmacological treatment of idiopathic inflammatory myopathies
    Fasano, Serena
    Alves, Sara Custodio
    Isenberg, David A.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (04) : 547 - 558
  • [4] Treatment of the inflammatory myopathies: update and practical recommendations
    Hengstman, Gerald J. D.
    van den Hoogen, Frank H. J.
    van Engelen, Baziel G. M.
    EXPERT OPINION ON PHARMACOTHERAPY, 2009, 10 (07) : 1183 - 1190
  • [5] Inflammatory myopathies
    Schoser, B.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2009, 68 (08): : 665 - 675
  • [6] Inflammatory myopathies
    Schoser, B.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2009, 68 (08): : 665 - 675
  • [7] Novel Therapeutic Options in Treatment of Idiopathic Inflammatory Myopathies
    Goyal, Namita A.
    Mozaffar, Tahseen
    CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2018, 20 (09)
  • [8] Novel Therapeutic Options in Treatment of Idiopathic Inflammatory Myopathies
    Namita A. Goyal
    Tahseen Mozaffar
    Current Treatment Options in Neurology, 2018, 20
  • [9] Rituximab in the treatment of inflammatory myopathies: a review
    Fasano, Serena
    Gordon, Patrick
    Hajji, Raouf
    Loyo, Esthela
    Isenberg, David A.
    RHEUMATOLOGY, 2017, 56 (01) : 26 - 36
  • [10] Diagnosis and treatment of the idiopathic inflammatory myopathies
    Gazeley, David J.
    Cronin, Mary E.
    THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2011, 3 (06) : 315 - 324